|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2018015526A1
(en)
|
2016-07-22 |
2018-01-25 |
Les Laboratoires Servier |
Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
|
|
JP6453507B2
(ja)
*
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
EP3668502A4
(en)
*
|
2017-08-15 |
2021-01-13 |
AbbVie Inc. |
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
|
|
CR20200124A
(es)
*
|
2017-08-15 |
2020-09-28 |
Abbvie Inc |
Inhibidores macrocíclicos de mcl-1 y métodos de uso
|
|
MA49908A
(fr)
|
2017-08-18 |
2021-04-28 |
Amgen Inc |
Composés inhibant la protéine mcl-1
|
|
US11279712B2
(en)
|
2017-08-29 |
2022-03-22 |
Amgen Inc. |
Macrocyclic compounds that inhibit MCL-1 protein
|
|
MA54985A
(fr)
*
|
2018-03-05 |
2021-12-29 |
Amgen Inc |
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
|
|
CN112118845B
(zh)
*
|
2018-05-14 |
2023-06-13 |
吉利德科学公司 |
Mcl-1抑制剂
|
|
US11130769B2
(en)
*
|
2018-11-09 |
2021-09-28 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020147802A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Macrocyclic spiroethers as mcl-1 inhibitors
|
|
CA3138058A1
(en)
|
2019-05-20 |
2020-11-26 |
Matthew T. Burger |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
JP7617861B2
(ja)
*
|
2019-06-21 |
2025-01-20 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１の大環状阻害剤
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
BR112022000251A2
(pt)
|
2019-07-09 |
2022-05-17 |
Janssen Pharmaceutica Nv |
Derivados macrocíclicos de espirociclo como inibidores de mcl-1
|
|
EP3771469A1
(en)
|
2019-07-30 |
2021-02-03 |
Amgen, Inc |
Formulations and dosages for administering a compound that inhibits mcl1 protein
|
|
WO2021047616A1
(zh)
*
|
2019-09-12 |
2021-03-18 |
苏州亚盛药业有限公司 |
氧氮杂环庚烷类螺环化合物、中间体及其制备方法
|
|
KR102902719B1
(ko)
|
2019-10-18 |
2025-12-24 |
포티 세븐, 엘엘씨 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
CN114786777A
(zh)
|
2019-11-04 |
2022-07-22 |
锐新医药公司 |
Ras抑制剂
|
|
PE20221277A1
(es)
*
|
2019-11-04 |
2022-09-05 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
PT4065567T
(pt)
*
|
2019-11-26 |
2024-11-08 |
Gilead Sciences Inc |
Processos e intermediários para a preparação de inibidores de mcl1
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
EP4107161A1
(en)
*
|
2020-02-21 |
2022-12-28 |
Janssen Pharmaceutica NV |
Macrocyclic indole derivatives as inhibitors of mcl-1
|
|
JP2021161114A
(ja)
*
|
2020-03-31 |
2021-10-11 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１化合物のメチル化
|
|
US20230212191A1
(en)
*
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
US12110294B2
(en)
|
2020-05-01 |
2024-10-08 |
Gilead Sciences, Inc. |
CD73 compounds
|
|
KR20230006550A
(ko)
|
2020-05-06 |
2023-01-10 |
암젠 인크 |
비닐 보호된 알코올 중간체의 합성
|
|
BR112022022474A2
(pt)
|
2020-05-06 |
2022-12-13 |
Amgen Inc |
Síntese de intermediários de sulfonamida
|
|
TWI867217B
(zh)
*
|
2020-05-06 |
2024-12-21 |
美商安進公司 |
乙烯基環丁基中間體之合成
|
|
TWI827924B
(zh)
*
|
2020-05-06 |
2024-01-01 |
美商安進公司 |
大環Mcl-1抑制劑中間體的閉環合成
|
|
US20230136910A1
(en)
*
|
2020-05-06 |
2023-05-04 |
Amgen Inc. |
Synthesis of vinylic alcohol intermediates
|
|
CN115698023A
(zh)
*
|
2020-06-10 |
2023-02-03 |
詹森药业有限公司 |
作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺
|
|
MX2023002691A
(es)
|
2020-09-03 |
2023-05-03 |
Amgen Inc |
Desimetrización de diol mediante sustitución aromática nucleófila.
|
|
AU2021345111B2
(en)
|
2020-09-15 |
2025-11-27 |
Revolution Medicines, Inc. |
Indole derivatives as Ras inhibitors in the treatment of cancer
|
|
JP7659630B2
(ja)
*
|
2020-11-19 |
2025-04-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
大環状ｍｃｌ１阻害剤を調製するための方法及び中間体
|
|
WO2022115451A1
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
BR112023010228A2
(pt)
*
|
2020-11-25 |
2023-10-17 |
Amgen Inc |
Alquenilação enantiosseletiva de aldeídos
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
WO2022122667A1
(en)
|
2020-12-07 |
2022-06-16 |
Cellestia Biotech Ag |
Pharmaceutical combinations for treating cancer
|
|
CN116670141A
(zh)
|
2020-12-17 |
2023-08-29 |
詹森药业有限公司 |
作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
JP2024516641A
(ja)
|
2021-04-26 |
2024-04-16 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
JP7673255B2
(ja)
|
2021-06-11 |
2025-05-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
|
|
TWI910028B
(zh)
|
2021-06-11 |
2025-12-21 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
JP2024544570A
(ja)
|
2021-11-16 |
2024-12-03 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
EP4504738A1
(en)
*
|
2022-04-05 |
2025-02-12 |
Amgen Inc. |
Amorphous and crystalline forms of mci-1 antagonists
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US12351588B2
(en)
|
2022-04-05 |
2025-07-08 |
Amgen Inc. |
Salt forms and solvates of Mcl-1 antagonists
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
PE20251072A1
(es)
|
2022-05-20 |
2025-04-10 |
Novartis Ag |
Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202540186A
(zh)
|
2023-11-22 |
2025-10-16 |
瑞士商諾華公司 |
抗ｃｄ７抗體藥物結合物及其使用方法
|
|
PY24103486A
(es)
|
2023-11-22 |
2025-06-06 |
Servier Lab |
Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|